Please fill in the form to download resources:
The FDA has been promoting continuous processing as a method to improve quality in pharmaceutical production since the publication of its Process Analytical Technology (PAT), highlighting the advantages of using the Quality by Design (QbD) and PAT philosophy. Manufacturing without interruption with a constant flow of materials fits very well within the concept of QbD. It provides many opportunities to adjust the process to meet the critical quality attributes and thus improve product quality.
GEA Pharma’s ConsiGma® continuous tableting line was developed in concurrence with the FDA’s QbD initiative and was designed to satisfy the industry’s need for continuous production to provide improved quality, flexibility, consistency for pharmaceutical processes and reducing cost per tablet. The ConsiGma® continuous high-shear mixing, drying and tabletting line has been designed in such a way that both R&D and production can use the same size of equipment, thus eliminating scale-up. Further advantages are a higher yield and very stable, plug flow-based process leading to increased quality levels and higher efficiency. In addition, development times are shorter, the total cost of ownership is reduced and energy consumption is lower. So far, more than 50 companies have tested over 80 different formulations at the GEA Process Development Centre in Belgium.
One system can run 500g in R&D – but can also run clinical trial, launch and production size batches. As there is no process scale-up, time is the only relevant factor in a continuous process – manufacturers are able to reduce development time dramatically, thereby reducing costs and bringing products to the market much faster.
At one-third of the size of a classic granulation line (inclusive of the tablet press) the system is very compact, while its modular construction allows it to fit perfectly into any R&D department or existing tablet production room. There is no need for any building alterations – the system is just wheeled in, connected to the power and air supply, and after a simple start-up period is ready to go. Installation time and cost are reduced to a fraction of the current benchmark. It is also possible to avoid high peak energy periods and run at continuous low energy consumption, helping companies meet their environmental obligations.
The ConsiGma® system is capable of undertaking particle design and mimicking any traditional batch granulation process – with a much higher and consistent quality resulting from its continuous production set-up and ‘risk-based approach’ to GMP. The granules have generally a better intra-granular porosity, with improved compressibility characteristics that help tablet presses run more efficiently at maximum speed with hardly any weight adjustments being required.
The full tablet production line consists of the ConsiGma® high-shear granulator and dryer, combined with the GEA rotary tablet press. A special in-line blender mixes in the external phase between the systems. The granulator and dryer section of the line has three modules: a wet high-shear granulation module, a segmented dryer module, and an evaluation module.
Contact Us
Please call us:
Make an enquiry:
We'll call you back: